EXTENSIVE-STAGE SMALL-CELL LUNG CANCER
Clinical trials for EXTENSIVE-STAGE SMALL-CELL LUNG CANCER explained in plain language.
Never miss a new study
Get alerted when new EXTENSIVE-STAGE SMALL-CELL LUNG CANCER trials appear
Sign up with your email to follow new studies for EXTENSIVE-STAGE SMALL-CELL LUNG CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo aims to hold back aggressive lung cancer
Disease control Not yet recruitingThis study tests whether adding the drug lurbinectedin to the immunotherapy durvalumab can help keep extensive-stage small-cell lung cancer from growing back after initial treatment. About 50 adults whose cancer did not worsen after first-line chemo plus durvalumab will receive t…
Matched conditions: EXTENSIVE-STAGE SMALL-CELL LUNG CANCER
Phase: PHASE2 • Sponsor: Jazz Pharmaceuticals • Aim: Disease control
Last updated Jun 17, 2026 03:13 UTC
-
New hope for tough lung cancer: drug duo tested in phase 2 trial
Disease control Not yet recruitingThis study tests whether adding lurbinectedin to paclitaxel works better than paclitaxel alone for people with advanced small cell lung cancer that got worse after first chemotherapy. About 69 adults will be randomly assigned to one of the two treatments. The goal is to see if th…
Matched conditions: EXTENSIVE-STAGE SMALL-CELL LUNG CANCER
Phase: PHASE2 • Sponsor: Yonsei University • Aim: Disease control
Last updated Jun 16, 2026 12:48 UTC
-
New drug combo targets tough lung cancer after standard therapy fails
Disease control Not yet recruitingThis study tests a combination of two drugs, sacituzumab tirumotecan and anlotinib, in people with extensive-stage small cell lung cancer whose disease has worsened after initial treatment with immunotherapy and chemotherapy. The goal is to see if this new combination can shrink …
Matched conditions: EXTENSIVE-STAGE SMALL-CELL LUNG CANCER
Phase: PHASE2 • Sponsor: China Medical University, China • Aim: Disease control
Last updated Jun 15, 2026 19:09 UTC
-
New hope for aggressive lung cancer: combo therapy enters phase 3 trial
Disease control Not yet recruitingThis phase 3 trial tests whether a new drug, BL-M14D1, combined with the immunotherapy atezolizumab works better than standard treatment for people with advanced small cell lung cancer that has spread. About 550 adults who have not had prior treatment will be randomly assigned to…
Matched conditions: EXTENSIVE-STAGE SMALL-CELL LUNG CANCER
Phase: PHASE3 • Sponsor: SystImmune Inc. • Aim: Disease control
Last updated Jun 15, 2026 19:03 UTC
-
Engineered immune cells take aim at deadliest lung cancer
Disease control Not yet recruitingThis early-phase study tests a personalized cell therapy for people with extensive-stage small cell lung cancer or similar neuroendocrine cancers that came back after standard treatment. Researchers take a patient's own immune cells, modify them to recognize a protein called B7-H…
Matched conditions: EXTENSIVE-STAGE SMALL-CELL LUNG CANCER
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 15, 2026 18:57 UTC
-
New hope for aggressive lung cancer: drug duo takes on chemo in major trial
Disease control Not yet recruitingThis study tests a new combination of drugs (BL-B01D1 and tislelizumab) against standard chemotherapy plus tislelizumab as the first treatment for people with extensive-stage small cell lung cancer, a fast-growing cancer. About 562 adults with good performance status will join th…
Matched conditions: EXTENSIVE-STAGE SMALL-CELL LUNG CANCER
Phase: PHASE3 • Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 09, 2026 12:09 UTC
-
Lung cancer study aims to improve treatment by watching Real-World care
Knowledge-focused Not yet recruitingThis study observes how patients with extensive-stage small cell lung cancer are treated in everyday hospital settings and how they respond. Researchers will collect medical records and track health over time, with optional blood and tissue samples for lab research. The goal is t…
Matched conditions: EXTENSIVE-STAGE SMALL-CELL LUNG CANCER
Sponsor: Peking Union Medical College Hospital • Aim: Knowledge-focused
Last updated Jun 10, 2026 13:26 UTC